Literature DB >> 29172863

Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update.

Arlene A Forastiere1, Nofisat Ismaila1, Jan S Lewin1, Cherie Ann Nathan1, David J Adelstein1, Avraham Eisbruch1, Gail Fass1, Susan G Fisher1, Scott A Laurie1, Quynh-Thu Le1, Bernard O'Malley1, William M Mendenhall1, Snehal Patel1, David G Pfister1, Anthony F Provenzano1, Randy Weber1, Gregory S Weinstein1, Gregory T Wolf1.   

Abstract

Purpose To update the guideline recommendations on the use of larynx-preservation strategies in the treatment of laryngeal cancer. Methods An Expert Panel updated the systematic review of the literature for the period from January 2005 to May 2017. Results The panel confirmed that the use of a larynx-preservation approach for appropriately selected patients does not compromise survival. No larynx-preservation approach offered a survival advantage compared with total laryngectomy and adjuvant therapy as indicated. Changes were supported for the use of endoscopic surgical resection in patients with limited disease (T1, T2) and for initial total laryngectomy in patients with T4a disease or with severe pretreatment laryngeal dysfunction. New recommendations for positron emission tomography imaging for the evaluation of regional nodes after treatment and best measures for evaluating voice and swallowing function were added. Recommendations Patients with T1, T2 laryngeal cancer should be treated initially with intent to preserve the larynx by using endoscopic resection or radiation therapy, with either leading to similar outcomes. For patients with locally advanced (T3, T4) disease, organ-preservation surgery, combined chemotherapy and radiation, or radiation alone offer the potential for larynx preservation without compromising overall survival. For selected patients with extensive T3 or large T4a lesions and/or poor pretreatment laryngeal function, better survival rates and quality of life may be achieved with total laryngectomy. Patients with clinically involved regional cervical nodes (N+) who have a complete clinical and radiologic imaging response after chemoradiation do not require elective neck dissection. All patients should undergo a pretreatment baseline assessment of voice and swallowing function and receive counseling with regard to the potential impact of treatment options on voice, swallowing, and quality of life. Additional information is available at www.asco.org/head-neck-cancer-guidelines and www.asco.org/guidelineswiki .

Entities:  

Mesh:

Year:  2017        PMID: 29172863     DOI: 10.1200/JCO.2017.75.7385

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  33 in total

1.  Organ-preservation (chemo)radiotherapy for T4 laryngeal and hypopharyngeal cancer: is the effort worth?

Authors:  Abrahim Al-Mamgani; Arash Navran; Iris Walraven; Willen Hans Schreuder; Margot E T Tesselaar; Willem Martin C Klop
Journal:  Eur Arch Otorhinolaryngol       Date:  2018-12-18       Impact factor: 2.503

2.  Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx: ASCO Clinical Practice Guideline.

Authors:  Shlomo A Koyfman; Nofisat Ismaila; Doug Crook; Anil D'Cruz; Cristina P Rodriguez; David J Sher; Damian Silbermins; Erich M Sturgis; Terance T Tsue; Jared Weiss; Sue S Yom; F Christopher Holsinger
Journal:  J Clin Oncol       Date:  2019-02-27       Impact factor: 44.544

3.  Surgical prevention of pharyngocutaneous fistula in salvage total laryngectomy: a systematic review and network meta-analysis.

Authors:  Armando De Virgilio; Andrea Costantino; Giuseppe Mercante; Fabio Ferreli; Bianca Maria Festa; Elena Russo; Luca Malvezzi; Raul Pellini; Giovanni Colombo; Giuseppe Spriano
Journal:  Eur Arch Otorhinolaryngol       Date:  2022-06-22       Impact factor: 2.503

4.  Low expression of isocitrate dehydrogenase 1 (IDH1) R132H is associated with advanced pathological features in laryngeal squamous cell carcinoma.

Authors:  Nasrin Shayanfar; Ali Zare-Mirzaie; Mahsa Mohammadpour; Ensieh Jafari; Amirhosein Mehrtash; Nikoo Emtiazi; Fatemeh Tajik
Journal:  J Cancer Res Clin Oncol       Date:  2022-09-05       Impact factor: 4.322

5.  Comparison of Survival Outcomes of Different Treatment Options for cT1-2, N0 Glottic Carcinoma: A Propensity Score-Weighted Analysis.

Authors:  Qi-Wei Liang; Liang Peng; Jing Liao; Chun-Xia Huang; Wei-Ping Wen; Wei Sun
Journal:  Front Surg       Date:  2022-05-20

Review 6.  Precision Medicine in Head and Neck Cancers: Genomic and Preclinical Approaches.

Authors:  Giacomo Miserocchi; Chiara Spadazzi; Sebastiano Calpona; Francesco De Rosa; Alice Usai; Alessandro De Vita; Chiara Liverani; Claudia Cocchi; Silvia Vanni; Chiara Calabrese; Massimo Bassi; Giovanni De Luca; Giuseppe Meccariello; Toni Ibrahim; Marco Schiavone; Laura Mercatali
Journal:  J Pers Med       Date:  2022-05-24

7.  Effect of a refined nursing model based on nursing quality feedback on the postoperative mental state of patients with laryngeal cancer.

Authors:  Kailian He; Quanqing Li; Yuqing Hou; Yulin He; Xiaozhen Yue
Journal:  Am J Transl Res       Date:  2021-06-15       Impact factor: 4.060

8.  Immune Cell Infiltrates and Neutrophil-to-Lymphocyte Ratio in Relation to Response to Chemotherapy and Prognosis in Laryngeal and Hypopharyngeal Squamous Cell Carcinomas.

Authors:  Mario Sánchez-Canteli; Luis Juesas; Esther Redin; Alfonso Calvo; Fernando López; Aurora Astudillo; Luis M Montuenga; Juana M García-Pedrero; Juan P Rodrigo
Journal:  Cancers (Basel)       Date:  2021-04-25       Impact factor: 6.639

9.  Stage Migration and Survival Trends in Laryngeal Cancer.

Authors:  Michael M Li; Songzhu Zhao; Antoine Eskander; Chandler Rygalski; Guy Brock; Anuraag S Parikh; Catherine T Haring; Brian Swendseid; Kevin Y Zhan; Carol R Bradford; Theodoros N Teknos; Ricardo L Carrau; Kyle K VanKoevering; Nolan B Seim; Matthew O Old; James W Rocco; Sidharth V Puram; Stephen Y Kang
Journal:  Ann Surg Oncol       Date:  2021-07-15       Impact factor: 4.339

10.  Early glottic cancer treatment with concurrent chemoradiotherapy with once-daily orally administered S-1.

Authors:  Yuuki Takase; Yoshiyuki Itoh; Kazuhiro Ohtakara; Mariko Kawamura; Junji Ito; Yumi Oie; Tamami Ono; Yutaro Sasaki; Ayumi Nishida; Shinji Naganawa
Journal:  Nagoya J Med Sci       Date:  2021-05       Impact factor: 1.131

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.